Madhumita Chatterjee1, Laura C Hurley1,2, Nancy K Levin1, Matthew Stack1, Michael A Tainsky1,2,3,4. 1. Department of Oncology, Wayne State University School of Medicine, Detroit, MI 48201, USA. 2. Cancer Biology Graduate Program, Wayne State University School of Medicine, Detroit, MI 48201, USA. 3. Molecular Therapeutics Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI 48201, USA. 4. Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, Detroit, MI 48201, USA.
Abstract
BACKGROUND: Ovarian cancer is frequently diagnosed at an advanced stage and 70% of patients experience recurrence months to years from initial diagnosis. The expression of paraneoplastic antigens can result in the occurrence of onconeural autoantibodies in ovarian cancer that may be associated with neurological disorders that are clinically manifested in patients before diagnosis of ovarian cancer. These paraneoplastic antigens can serve as excellent biomarkers not only for early detection but also for monitoring ovarian cancer recurrence. OBJECTIVE: To assess the immunoreactivity of our previous 3 biomarkers along with 3 paraneoplastic antigens, HARS, Ro52 and CDR2 for the evaluation of their sensitivity in predicting recurrence before the clinical relapse of the ovarian cancer. METHODS: Western blot immunoassays were performed to assess the immunoreactivity of 6 antigens with 21 recurrent ovarian cancer patients. RESULTS: The results indicated that antibodies to HARS, Ro52, CDR2 and 5H6 antigens predicted ovarian cancer recurrence 5.03 months before the clinical or symptomatic relapse in 21 ovarian cancer patients with a sensitivity of 90.5% when CA125 levels were below the standard cutoff (35 U/ml). CONCLUSION: Our study suggests that appearance of onconeural antibodies prior to the rise in CA125 during post treatment surveillance can be a useful diagnostic to predict ovarian cancer recurrence.
BACKGROUND:Ovarian cancer is frequently diagnosed at an advanced stage and 70% of patients experience recurrence months to years from initial diagnosis. The expression of paraneoplastic antigens can result in the occurrence of onconeural autoantibodies in ovarian cancer that may be associated with neurological disorders that are clinically manifested in patients before diagnosis of ovarian cancer. These paraneoplastic antigens can serve as excellent biomarkers not only for early detection but also for monitoring ovarian cancer recurrence. OBJECTIVE: To assess the immunoreactivity of our previous 3 biomarkers along with 3 paraneoplastic antigens, HARS, Ro52 and CDR2 for the evaluation of their sensitivity in predicting recurrence before the clinical relapse of the ovarian cancer. METHODS: Western blot immunoassays were performed to assess the immunoreactivity of 6 antigens with 21 recurrent ovarian cancerpatients. RESULTS: The results indicated that antibodies to HARS, Ro52, CDR2 and 5H6 antigens predicted ovarian cancer recurrence 5.03 months before the clinical or symptomatic relapse in 21 ovarian cancerpatients with a sensitivity of 90.5% when CA125 levels were below the standard cutoff (35 U/ml). CONCLUSION: Our study suggests that appearance of onconeural antibodies prior to the rise in CA125 during post treatment surveillance can be a useful diagnostic to predict ovarian cancer recurrence.
Authors: Madhumita Chatterjee; Saroj Mohapatra; Alexei Ionan; Gagandeep Bawa; Rouba Ali-Fehmi; Xiaoju Wang; James Nowak; Bin Ye; Fatimah A Nahhas; Karen Lu; Steven S Witkin; David Fishman; Adnan Munkarah; Robert Morris; Nancy K Levin; Natalie N Shirley; Gerard Tromp; Judith Abrams; Sorin Draghici; Michael A Tainsky Journal: Cancer Res Date: 2006-01-15 Impact factor: 12.701
Authors: Gordon J S Rustin; Maria E L van der Burg; Clare L Griffin; David Guthrie; Alan Lamont; Gordon C Jayson; Gunnar Kristensen; César Mediola; Corneel Coens; Wendi Qian; Mahesh K B Parmar; Ann Marie Swart Journal: Lancet Date: 2010-10-02 Impact factor: 79.321
Authors: Cecilie Totland; Nina K Aarskog; Tilo W Eichler; Mette Haugen; Jane K Nøstbakken; Sissel E Monstad; Helga B Salvesen; Sverre Mørk; Bjørn I Haukanes; Christian A Vedeler Journal: Cancer Immunol Immunother Date: 2010-11-16 Impact factor: 6.968
Authors: O M Zack Howard; Hui Fang Dong; De Yang; Nina Raben; Kanneboyina Nagaraju; Antony Rosen; Livia Casciola-Rosen; Michael Härtlein; Michael Kron; David Yang; Kwabena Yiadom; Sunita Dwivedi; Paul H Plotz; Joost J Oppenheim Journal: J Exp Med Date: 2002-09-16 Impact factor: 14.307
Authors: Vitor M Faça; Aviva P Ventura; Mathew P Fitzgibbon; Sandra R Pereira-Faça; Sharon J Pitteri; Ann E Green; Renee C Ireton; Qing Zhang; Hong Wang; Kathy C O'Briant; Charles W Drescher; Michèl Schummer; Martin W McIntosh; Beatrice S Knudsen; Samir M Hanash Journal: PLoS One Date: 2008-06-18 Impact factor: 3.240
Authors: Pierluigi Giampaolino; Virginia Foreste; Luigi Della Corte; Claudia Di Filippo; Giuseppe Iorio; Giuseppe Bifulco Journal: Gland Surg Date: 2020-08
Authors: Laura C Hurley; Nancy K Levin; Madhumita Chatterjee; Jasmine Coles; Shlomo Muszkat; Zachary Howarth; Gregory Dyson; Michael A Tainsky Journal: Cancer Biomark Date: 2020 Impact factor: 4.388